Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Data from First Set of 24-week Biopsies Expected Q2 or Q3 for UK Enrolled DMD patients in the Ongoing PhaseOut DMD trial

Source Link:: http://seekingalpha.com/article/3973706-summit-therapeutics-smmt-ceo-glyn-edwards-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

33%

33%

66%

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Management Comment We had experienced expected enrollments to begin earlier in the year, but getting the site started up has taken longer than we had anticipated and we now expect enrollments in the UK to begin this quarter. As a result, we are expecting data from the first set of 24-week biopsies in January 2017. These biopsies could provide early proof of mechanism data for ezutromid and utrophin modulation and we eagerly await these results.

http://seekingalpha....

Additional Relevant Details Update 12/15/2016:
"PhaseOut DMD, our Phase 2 proof of concept trial of ezutromid, is enrolling now in the UK and the US, and we are on track to report data from the first group of 24-week biopsies in the second or third quarter of 2017."

http://seekingalpha....